TGTX — TG Therapeutics Share News
0.000.00%
Last trade - 00:00- $8.57bn
- $8.77bn
- $616.29m
Brief: TG Therapeutics Provides Business Update And Reports First Quarter 2023 Financial Results
Brief: TG Therapeutics posts Q1 EPS USD -0.28
Brief: Tg Therapeutics Announces Issuance Of Permanent J-Code For Briumvi® (Ublituximab-Xiiy) From Centers For Medicare And Medicaid Services
Brief: Tg Therapeutics Announces Presentation Of Data From The Ultimate I & Ii Phase 3 Trials Of Briumvi® (Ublituximab-Xiiy) In Multiple Sclerosis
TG Therapeutics soars as Cantor Fitzgerald sees sclerosis drug sales to beat estimates
U.S. STOCKS ON THE MOVE-Icosavax, U.S. solar companies, Nikola, energy firms
TG Therapeutics rises as European regulator backs multiple sclerosis drug
TG Therapeutics rises as European regulator backs multiple sclerosis drug
Brief: TG Therapeutics Announces Positive CHMP Opinion For BRIUMVI
US FDA moots more rigorous trials for accelerated nod of cancer therapy (updated)
US FDA seeks more rigorous trials for cancer drugs' accelerated nod
TG Therapeutics Inc reports results for the quarter ended in December - Earnings Summary
Brief: Tg Therapeutics Provides Business Update And Reports Fourth Quarter And Year-End 2022 Financial Results
TG Therapeutics Inc expected to post a loss of 26 cents a share - Earnings Preview
Brief: TG Therapeutics To Present Data From The Ultimate I & II Phase 3 Trials Of BRIUMVI(ublituximab-xiiy)
Brief: TG Therapeutics Announces Data Presentations From The Ultimate I & II Phase 3 Trials Of Briumvi (Ublituximab) In Multiple Sclerosis To Be Presented
U.S. STOCKS ON THE MOVE-Foot Locker, Nemaura, Chipotle
U.S. STOCKS ON THE MOVE-TD Synnex, Nucor, Pfizer
U.S. STOCKS ON THE MOVE-Xerox, AC Immune, OpGen